Sarepta Therapeutics, Inc. (0L35.L)
USD 51.97
(0.6%)
USD 51.97
(0.6%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.24 Billion USD | 33.26% |
| 2022 | 933.01 Million USD | 32.93% |
| 2021 | 701.88 Million USD | 29.96% |
| 2020 | 540.09 Million USD | 41.82% |
| 2019 | 380.83 Million USD | 26.51% |
| 2018 | 301.03 Million USD | 94.74% |
| 2017 | 154.58 Million USD | 2751.58% |
| 2016 | 5.42 Million USD | 332.64% |
| 2015 | 1.25 Million USD | -87.16% |
| 2014 | 9.75 Million USD | -31.38% |
| 2013 | 14.21 Million USD | -61.91% |
| 2012 | 37.32 Million USD | -20.56% |
| 2011 | 46.99 Million USD | 59.72% |
| 2010 | 29.42 Million USD | 67.3% |
| 2009 | 17.58 Million USD | -17.28% |
| 2008 | 21.25 Million USD | 93.52% |
| 2007 | 10.98 Million USD | 9428.23% |
| 2006 | 115.29 Thousand USD | -97.59% |
| 2005 | 4.78 Million USD | 1011.31% |
| 2004 | 430.46 Thousand USD | -55.62% |
| 2003 | 969.86 Thousand USD | 15.9% |
| 2002 | 836.78 Thousand USD | 18.51% |
| 2001 | 706.1 Thousand USD | -45.57% |
| 2000 | 1.29 Million USD | 1197.34% |
| 1999 | 100 Thousand USD | -50.0% |
| 1998 | 200 Thousand USD | 100.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 413.46 Million USD | 4.2% |
| 2024 Q2 | 362.93 Million USD | -12.22% |
| 2023 Q2 | 261.23 Million USD | 3.05% |
| 2023 Q4 | 396.78 Million USD | 19.58% |
| 2023 Q3 | 331.81 Million USD | 27.02% |
| 2023 FY | 1.24 Billion USD | 33.26% |
| 2023 Q1 | 253.5 Million USD | -1.91% |
| 2022 Q3 | 230.26 Million USD | -1.38% |
| 2022 FY | 933.01 Million USD | 32.93% |
| 2022 Q4 | 258.42 Million USD | 12.23% |
| 2022 Q1 | 210.83 Million USD | 4.65% |
| 2022 Q2 | 233.48 Million USD | 10.75% |
| 2021 Q4 | 201.46 Million USD | 6.36% |
| 2021 Q1 | 146.93 Million USD | 1.24% |
| 2021 Q2 | 164.08 Million USD | 11.68% |
| 2021 FY | 701.88 Million USD | 29.96% |
| 2021 Q3 | 189.4 Million USD | 15.43% |
| 2020 Q3 | 143.92 Million USD | 4.78% |
| 2020 FY | 540.09 Million USD | 41.82% |
| 2020 Q1 | 113.67 Million USD | 13.55% |
| 2020 Q2 | 137.36 Million USD | 20.84% |
| 2020 Q4 | 145.13 Million USD | 0.84% |
| 2019 Q3 | 99.04 Million USD | 4.62% |
| 2019 Q1 | 87.01 Million USD | 3.08% |
| 2019 Q2 | 94.66 Million USD | 8.8% |
| 2019 Q4 | 100.11 Million USD | 1.08% |
| 2019 FY | 380.83 Million USD | 26.51% |
| 2018 Q1 | 64.6 Million USD | 12.79% |
| 2018 Q4 | 84.41 Million USD | 7.55% |
| 2018 Q3 | 78.48 Million USD | 6.74% |
| 2018 FY | 301.03 Million USD | 94.74% |
| 2018 Q2 | 73.52 Million USD | 13.81% |
| 2017 Q4 | 57.27 Million USD | 24.64% |
| 2017 FY | 154.58 Million USD | 2751.58% |
| 2017 Q3 | 45.95 Million USD | 31.26% |
| 2017 Q2 | 35.01 Million USD | 114.24% |
| 2017 Q1 | 16.34 Million USD | 201.46% |
| 2016 Q4 | 5.42 Million USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | 5.42 Million USD | 332.64% |
| 2016 Q1 | - USD | -100.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 FY | 1.25 Million USD | -87.16% |
| 2015 Q4 | 1.25 Million USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2014 FY | 9.75 Million USD | -31.38% |
| 2014 Q2 | 2.58 Million USD | -57.57% |
| 2014 Q3 | 1.05 Million USD | -59.0% |
| 2014 Q4 | 27 Thousand USD | -97.45% |
| 2014 Q1 | 6.08 Million USD | 131.84% |
| 2013 Q2 | 2.95 Million USD | -34.04% |
| 2013 Q3 | 4.16 Million USD | 41.24% |
| 2013 Q4 | 2.62 Million USD | -37.0% |
| 2013 Q1 | 4.47 Million USD | -39.01% |
| 2013 FY | 14.21 Million USD | -61.91% |
| 2012 FY | 37.32 Million USD | -20.56% |
| 2012 Q1 | 11.21 Million USD | -17.47% |
| 2012 Q2 | 11.2 Million USD | -0.04% |
| 2012 Q3 | 7.57 Million USD | -32.42% |
| 2012 Q4 | 7.33 Million USD | -3.14% |
| 2011 Q3 | 7.52 Million USD | -35.05% |
| 2011 Q1 | 14.29 Million USD | -7.87% |
| 2011 Q4 | 13.58 Million USD | 80.56% |
| 2011 Q2 | 11.58 Million USD | -18.96% |
| 2011 FY | 46.99 Million USD | 59.72% |
| 2010 Q1 | 1.2 Million USD | -76.56% |
| 2010 FY | 29.42 Million USD | 67.3% |
| 2010 Q2 | 3.99 Million USD | 231.7% |
| 2010 Q3 | 8.7 Million USD | 117.71% |
| 2010 Q4 | 15.51 Million USD | 78.32% |
| 2009 FY | 17.58 Million USD | -17.28% |
| 2009 Q3 | 6.34 Million USD | 115.59% |
| 2009 Q4 | 5.14 Million USD | -19.03% |
| 2009 Q2 | 2.94 Million USD | -6.51% |
| 2009 Q1 | 3.15 Million USD | -42.52% |
| 2008 FY | 21.25 Million USD | 93.52% |
| 2008 Q3 | 5.17 Million USD | 3.77% |
| 2008 Q2 | 4.98 Million USD | -11.41% |
| 2008 Q1 | 5.62 Million USD | 8.45% |
| 2008 Q4 | 5.47 Million USD | 5.98% |
| 2007 Q2 | 2.35 Million USD | 338.66% |
| 2007 FY | 10.98 Million USD | 9428.23% |
| 2007 Q4 | 5.18 Million USD | 78.14% |
| 2007 Q3 | 2.91 Million USD | 23.81% |
| 2007 Q1 | 536.04 Thousand USD | 2959.78% |
| 2006 FY | 115.29 Thousand USD | -97.59% |
| 2006 Q4 | 17.51 Thousand USD | 32.2% |
| 2006 Q3 | 13.25 Thousand USD | -28.59% |
| 2006 Q2 | 18.55 Thousand USD | -71.87% |
| 2006 Q1 | 65.96 Thousand USD | -95.35% |
| 2005 Q2 | 39.31 Thousand USD | -13.0% |
| 2005 Q1 | 45.19 Thousand USD | -84.18% |
| 2005 Q4 | 1.41 Million USD | -56.81% |
| 2005 Q3 | 3.28 Million USD | 8247.04% |
| 2005 FY | 4.78 Million USD | 1011.31% |
| 2004 FY | 430.46 Thousand USD | -55.62% |
| 2004 Q3 | 9151.00 USD | -74.77% |
| 2004 Q4 | 285.58 Thousand USD | 3020.84% |
| 2004 Q2 | 36.27 Thousand USD | -63.53% |
| 2004 Q1 | 99.45 Thousand USD | -26.43% |
| 2003 Q1 | 257.92 Thousand USD | 52.43% |
| 2003 Q4 | 135.18 Thousand USD | -67.38% |
| 2003 FY | 969.86 Thousand USD | 15.9% |
| 2003 Q2 | 162.41 Thousand USD | -37.03% |
| 2003 Q3 | 414.35 Thousand USD | 155.13% |
| 2002 Q4 | 169.2 Thousand USD | -27.13% |
| 2002 Q1 | 237.69 Thousand USD | -19.51% |
| 2002 Q2 | 197.69 Thousand USD | -16.83% |
| 2002 Q3 | 232.19 Thousand USD | 17.45% |
| 2002 FY | 836.78 Thousand USD | 18.51% |
| 2001 Q4 | 295.3 Thousand USD | -3.98% |
| 2001 FY | 706.1 Thousand USD | -45.57% |
| 2001 Q3 | 307.54 Thousand USD | 252.44% |
| 2001 Q2 | 87.26 Thousand USD | 446.08% |
| 2001 Q1 | 15.98 Thousand USD | -36.08% |
| 2000 Q3 | 122.21 Thousand USD | 569.67% |
| 2000 Q2 | 18.25 Thousand USD | -98.39% |
| 2000 FY | 1.29 Million USD | 1197.34% |
| 2000 Q1 | 1.13 Million USD | 0.0% |
| 2000 Q4 | 25 Thousand USD | -79.54% |
| 1999 Q1 | 100 Thousand USD | 0.0% |
| 1999 FY | 100 Thousand USD | -50.0% |
| 1999 Q3 | 100 Thousand USD | 0.0% |
| 1999 Q4 | - USD | -100.0% |
| 1999 Q2 | 100 Thousand USD | 0.0% |
| 1998 Q2 | 100 Thousand USD | 0.0% |
| 1998 FY | 200 Thousand USD | 100.0% |
| 1998 Q4 | 100 Thousand USD | 0.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 900.0% |
| 1997 Q2 | 100 Thousand USD | 0.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q4 | - USD | -100.0% |
| 1996 Q3 | 20 Thousand USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q4 | 10 Thousand USD | -50.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 97.099% |
| Dynavax Technologies Corporation | 232.28 Million USD | -435.265% |
| Illumina, Inc. | 4.5 Billion USD | 72.395% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 91.702% |
| Biogen Inc. | 9.83 Billion USD | 87.359% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -104469.891% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 67.18% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -104.657% |
| Waters Corporation | 2.95 Billion USD | 57.944% |
| Perrigo Company plc | 4.65 Billion USD | 73.294% |
| uniQure N.V. | 15.84 Million USD | -7747.857% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -4535.335% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -211.335% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -14402.928% |
| bluebird bio, Inc. | 29.49 Million USD | -4115.127% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -5829.683% |
| Imunon, Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 678.4 Million USD | -83.275% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 34.114% |
| Nektar Therapeutics | 90.12 Million USD | -1279.614% |
| Editas Medicine, Inc. | 78.12 Million USD | -1491.511% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.158% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -878.666% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 48.606% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -605.511% |
| Evolus, Inc. | 202.08 Million USD | -515.254% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -3878.803% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 90.521% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -968.764% |
| FibroGen, Inc. | 147.75 Million USD | -741.502% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 81.804% |
| OPKO Health, Inc. | 863.49 Million USD | -43.989% |
| Homology Medicines, Inc. | -6.65 Million USD | 18793.971% |
| Geron Corporation | 237 Thousand USD | -524514.346% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 31.995% |
| Exelixis, Inc. | 1.83 Billion USD | 32.066% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -3327.529% |
| Zoetis Inc. | 8.54 Billion USD | 85.448% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -359.474% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -35423.886% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 87.402% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -57.854% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -157.753% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -49.934% |
| Blueprint Medicines Corporation | 249.38 Million USD | -398.571% |
| Insmed Incorporated | 305.2 Million USD | -307.373% |
| TG Therapeutics, Inc. | 233.66 Million USD | -432.109% |
| Incyte Corporation | 3.69 Billion USD | 66.357% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -18.492% |